OVID Stock Summary and Trading Ideas (Ovid Therapeutics | NASDAQ:OVID)

Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.

Ovid Therapeutics trades on the NASDAQ stock market under the symbol OVID.

As of October 2, 2026, OVID stock price declined to $2.38 with 2,083,900 million shares trading.

OVID has a beta of 1.58, meaning it tends to be more sensitive to market movements. OVID has a correlation of 0.05 to the broad based SPY ETF.

OVID has a market cap of $464.81 million. This is considered a Small Cap stock.

Last quarter Ovid Therapeutics reported $733,000 in Revenue and -$.08 earnings per share. This beat revenue expectation by $703,000 and exceeded earnings estimates by $.02.

In the last 3 years, OVID traded as high as $4.10 and as low as $.24.

The top ETF exchange traded funds that OVID belongs to (by Net Assets): VTI, IWM, XBI, VXF, IWN.

OVID has outperformed the market in the last year with a return of +45.1%, while the SPY ETF gained +16.1%. However, in the most recent history, OVID shares have underperformed the stock market with its stock returning -11.5% in the last 3 month period and -11.5% for the last 2 week period, while SPY has returned +3.6% and +1.0%, respectively.

OVID support price is $2.35 and resistance is $2.51 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OVID shares will trade within this expected range on the day.